Earnings call transcript: Australian Clinical Labs jumps 15.5% after FY 2026 profit gains

Australian Clinical Labs reported a 15.5% increase in its FY 2026 earnings, despite a decline in revenue within the weak pathology market. The company credited tighter cost control, improved billing, and a shift towards more profitable private work for driving the earnings growth. The stock price rose 15.53% to $2.72 following the earnings call, nearing the top of its 52-week range.

While revenue dipped compared to the previous year, the company managed to keep labor costs under control, increase productivity, and enhance margins.

The company's performance indicated scale advantages, as it is the only national pathology provider using a single laboratory information system. This platform supports efficiency, billing, and integration across the network, helping to improve profitability even if market growth remains subdued. Australian Clinical Labs maintained a strong position with a net debt of AUD 37.4 million, equivalent to 0.5 times underlying EBITDA.

The company's P/E ratio stands at 15.89, and it has a debt-to-equity ratio of 2.09. Its Financial Health score is rated as GREAT, particularly for profitability.

Underlying EBIT margin expanded to 9.4%, and second-half margin reached 11%, aligning with management's guidance. EPS and underlying NPAT also grew, highlighting earnings growth despite a lower revenue base. The company's dividend yield of 5.5%, with a payout ratio of 69% of underlying NPAT and AUD 21.8 million in buybacks, likely attracted investors. The significant gain in the stock price, despite a soft market, suggests a positive reassessment of the company's earnings quality and future opportunities.

For FY 2027, the company anticipates revenue between AUD 745 million and AUD 765 million and underlying EBIT of AUD 67 million to AUD 73 million, resulting in an EBIT margin of approximately 9.0% to 9.5%. Management acknowledged modest market growth and the impact of internal initiatives, such as the single laboratory information system, wage pressures, and billing program enhancements.

CEO Melinda McGrath emphasized the company's ability to deliver earnings growth in a historically low-growth pathology market and the importance of its footprint redesign and lab-efficiency improvements.